There are currently 125 active clinical trials seeking participants for Melanoma research studies. The states with the highest number of trials for Melanoma participants are California, Texas, New York and Florida.
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
NCT05373823
Recruiting
This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e.g., cost, adoption) as well as contextual factors important for scale-up in community and health care settings where melanoma survivors receive follow-up care. A type 1 hybrid effectiveness-implementation design allows us to engage multilevel stakeholders throughout this process, evaluate the effec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Melanoma
Register for Updates
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
NCT06771544
Recruiting
This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California
Conditions: Melanoma, Melanoma Stage III, Melanoma (Skin), Melanoma Stage IV
Register for Updates
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT04895709
Recruiting
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Community Cancer Institute, Clovis, California +46 locations
Conditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Register for Updates
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
NCT05830058
Recruiting
This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligoprogression) compared to standard SBRT. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and caus... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/29/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
Register for Updates
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
NCT05877430
Recruiting
Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of California, Irvine, Irvine, California +3 locations
Conditions: NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
Register for Updates
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678
Recruiting
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: University of California, San Francisco (UCSF), San Francisco, California +8 locations
Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
Register for Updates
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
NCT05105100
Recruiting
This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor microenvironment (TME) can predict response and resistance to immunotherapy. These systemic tumor directed T cells can be defined by tumor/blood small conditional RNA (scRNA) using T cell receptor (TCR) as a barcode and can help predict response to PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Melanoma, Advanced Melanoma
Register for Updates
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
NCT04594187
Recruiting
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of patients with more advanced melanoma have shown nodal radiation therapy can decrease the risk of nodal recurrence but it is not known if this same benefit will be seen in patients with high risk sentinel lymph node positive di... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Baptist - MD Anderson Cancer Center, Jacksonville, Florida +2 locations
Conditions: Melanoma
Register for Updates
A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369
Recruiting
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Florida Cancer Specialists, Lake Mary, Florida +2 locations
Conditions: Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Register for Updates
Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
NCT05461430
Recruiting
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: xCures, Oakland, California
Conditions: Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Register for Updates
Video Education With Result Dependent dIsclosure
NCT05225428
Recruiting
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
Register for Updates
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
NCT04464759
Recruiting
This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Melanoma
Register for Updates